Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

  • End date
    Dec 3, 2024
  • participants needed
  • sponsor
    Trillium Therapeutics Inc.
Updated on 4 October 2022
measurable disease
ovarian cancer
fallopian tube
ovarian epithelial carcinoma
cancer of the ovary
platinum-resistant ovarian cancer


This is a multi-center, open-label study designed to evaluate TTI-622 administered in combination with Pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Approximately 50 patients will be enrolled in the study (this includes two phases, the Dose Escalation and Dose Expansion).


Pegylated liposomal doxorubicin (PLD) is a standard treatment option for patients with platinum-resistant ovarian cancer who are not candidates for chemotherapy in combination with bevacizumab. However, despite being consider a standard treatment option, the clinical benefit of chemotherapy for this patient population is small. The goal of this clinical trial is to improve upon the activity of PLD in a safe manner to provide a more effective therapeutic option for this group of patients.

TTI-622-02 is a multi-center, open-label study designed to evaluate TTI-622 administered in combination with PLD in patients with platinum-resistant ovarian cancer and for whom PLD is a reasonable treatment option. The first portion of the study will evaluate the safety of increasing dose levels of TTI-622 in combination with PLD at 40 mg/m2 in patients with platinum-resistant EOC, including ovarian, peritoneal and fallopian tube malignancy, and establish a combination regimen for further evaluation in a dose expansion cohort. The study will consist of a 28-day screening period, a treatment period in which patients will receive TTI-622 in combination with PLD in 28-day cycles until documentation of objective disease progression or development of unacceptable toxicity, and a long-term follow-up period to assess overall survival.

Condition Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Treatment Pegylated Liposomal Doxorubicin, TTI-622
Clinical Study IdentifierNCT05261490
SponsorTrillium Therapeutics Inc.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Histologically-confirmed epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC)
Platinum-resistant disease (progression ≥1 month and ≤6 months after a minimum of four cycles of last platinum-based treatment)
Progression with standard of care therapies, including platinum-based therapies, poly ADP ribose polymerase (PARP) inhibitors or bevacizumab in the platinum-sensitive setting or intolerability to such therapies or patient refusal
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Adequate organ and hematologic function
No more than four prior treatment regimens for platinum-resistant disease
All adverse events from prior treatment must be the Common Terminology Criteria for Adverse Events (NCI CTCAE) v5 Grade ≤ 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline

Exclusion Criteria

Platinum-refractory disease (defined as progression on or within 3 months of completing primary first-line platinum-based treatment)
Non-epithelial histology, including malignant mixed Mullerian tumors
Ovarian tumors with low malignant potential (i.e., borderline tumors), low grade serous ovarian cancer or carcinosarcoma
History of acute coronary syndromes
History of or current Class II, III, or IV heart failure
History or evidence of known central nervous system (CNS) metastases or carcinomatous meningitis
Significant bleeding disorders, vasculitis or a significant bleeding episode from the Gastrointestinal (GI) tract
History of severe hypersensitivity reactions to antibodies
Systemic steroid therapy
History or autoimmune disease that has required systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs
Prior organ transplantation including allogenic or autologous stem cell transplantation
Prior treatment with anti-cluster of differentiation 47 (CD47) or anti-SIRPα therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note